Immunogenicity and Toxicity of Different Adjuvants Can Be Characterized by Profiling Lung Biomarker Genes After Nasal Immunization
The efficacy of vaccine adjuvants depends on their ability to appropriately enhance the immunogenicity of vaccine antigens, which is often insufficient in non-adjuvanted vaccines. Genomic analyses of immune responses elicited by vaccine adjuvants provide information that is critical for the rational...
Main Authors: | Eita Sasaki, Hideki Asanuma, Haruka Momose, Keiko Furuhata, Takuo Mizukami, Isao Hamaguchi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.02171/full |
Similar Items
-
Modeling for influenza vaccines and adjuvants profile for safety prediction system using gene expression profiling and statistical tools.
by: Eita Sasaki, et al.
Published: (2018-01-01) -
Riboflavin as a Mucosal Adjuvant for Nasal Influenza Vaccine
by: Yinyan Yin, et al.
Published: (2021-11-01) -
In vitro marker gene expression analyses in human peripheral blood mononuclear cells: A tool to assess safety of influenza vaccines in humans
by: Eita Sasaki, et al.
Published: (2018-01-01) -
Nasal Immunization With Small Molecule Mast Cell Activators Enhance Immunity to Co-Administered Subunit Immunogens
by: Brandi T. Johnson-Weaver, et al.
Published: (2021-09-01) -
Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine
by: Kaito A. Nagashima, et al.
Published: (2021-03-01)